Comparative Efficacy of Triazolam, Flurazepam and Placebo in Out-Patients Insomniacs

1978 ◽  
Vol 6 (4) ◽  
pp. 337-342 ◽  
Author(s):  
Angela J Bowen
Keyword(s):  
Crossover Trial ◽  
Sleep Onset ◽  
Quality Of Sleep ◽  
Comparative Efficacy ◽  
Short Term ◽  
Night Time ◽  
Double Blind ◽  
Hypnotic Efficacy ◽  
Better Than

The short-term hypnotic efficacy of triazolam was compared to that of flurazepam and placebo in 120 out-patient insomniacs. Each patient was studied with a two-night, double-blind crossover trial. Triazolam (0.5 mg) was compared to placebo and flurazepam (30 mg). Triazolam (0.25 mg) was compared to flurazepam (15 mg and 30 mg). Triazolam (0.5 mg) was preferred to both placebo and flurazepam (30 mg). Triazolam (0.5 mg) was superior to placebo in improving quality of sleep, shortening sleep onset, increasing sleep duration, and reducing the number of night-time awakenings. Triazolam (0.5 mg) was superior to flurazepam (30 mg) in speeding sleep onset and increasing the quality of sleep. Triazolam (0.25 mg) was preferred to flurazepam (15 mg) and was significantly better than flurazepam on all sleep questions. Triazolam (0.25 mg) was preferred by more patients than flurazepam (30 mg) and was judged equally efficacious on indivdual sleep questions. Reports of side-effects were minimal for both drugs.

A Clinical Comparison of Triazolam with Placebo and with Secobarbital in Insomniac Patients

1978 ◽  
Vol 6 (4) ◽  
pp. 343-347 ◽  
Author(s):  
K Kay Okawa ◽  
George S Allen
Keyword(s):  
Side Effects ◽  
Sleep Duration ◽  
Sleep Onset ◽  
Questionnaire Data ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Sleep Questionnaire ◽  
Clinical Comparison ◽  
Hypnotic Efficacy ◽  
Better Than

Seventy-six out-patient insomniacs participated in three different two-night, double-blind crossover trials investigating the hypnotic efficacy and safety of triazolam. Triazolam 0.5 mg was compared to placebo in one trial conducted by K Kay Okawa, MD, and triazolam 0.5 mg was compared to secobarbital 100 mg in trials conducted by K Kay Okawa, MD and George S Allen, MD. The results of the latter two studies were combined and the data analyzed jointly. Triazolam 0.5 mg was found to be preferred and to be significantly better than both placebo and secobarbital 100 mg in the treatment of insomnia. Analysis of sleep questionnaire data showed triazolam to be superior to either placebo or secobarbital on the following parameters: how much the medication helped the patient sleep; onset of sleep; duration of sleep; and number of nocturnal awakenings. No differences were observed between treatments in any trial with regard to the patient's feeling of alertness the next morning. The side-effects reported for all treatments did not significantly interfere with the patients' ability to function.

A Clinical Trial of Electrosleep Therapy with a Psychiatric Inpatient Sample

1975 ◽  
Vol 9 (4) ◽  
pp. 287-290 ◽  
Author(s):  
Eugene A. Levitt ◽  
Norman McI. James ◽  
Philippa Flavell
Keyword(s):  
Clinical Trial ◽  
Psychiatric Inpatient ◽  
The Other ◽  
Quality Of Sleep ◽  
Double Blind ◽  
Symptoms Of Depression ◽  
Treatment Of Depression ◽  
Sleep Difficulties ◽  
Better Than

The study assessed the effectiveness of electrosleep therapy in the treatment of depression, anxiety, and sleep difficulties in a small, heterogeneous sample of psychiatric inpatients. A double-blind format was employed, one group receiving active treatment while the other received simulated treatment. The results showed active electrosleep to be no better than placebo in bettering quality of sleep or in lessening symptoms of depression or anxiety.

Evaluation of the Short-Term Treatment of Insomnia in Out-Patients with 15 Milligrams of Quazepam

1983 ◽  
Vol 11 (3) ◽  
pp. 155-161 ◽  
Author(s):  
Joseph Mendels ◽  
S Stern
Keyword(s):  
Term Treatment ◽  
Double Blind Study ◽  
Short Term ◽  
Short Term Treatment ◽  
Double Blind ◽  
Adverse Experiences ◽  
Hypnotic Agent ◽  
Low Incidence ◽  
Hypnotic Efficacy

The short-term safety and hypnotic efficacy of 15 mg of quazepam was compared with that of placebo in a double-blind study in sixty out-patients with insomnia. All patients received placebo for 3 consecutive nights to establish a baseline; for the next 5 nights thirty patients received quazepam and thirty received placebo. The results indicated that quazepam was significantly more effective than placebo in terms of quantity and quality of sleep and that quazepam was effective on the first night. Despite having a marked hypnotic effect, quazepam was not different from placebo in terms of hang-over effects (i.e., ease in awakening and alertness) the following morning. Treatment-related adverse experiences were reported by ten patients who received quazepam and by five who received only placebo. The most frequently reported adverse experience was daytime somnolence. This study demonstrates that quazepam, in a 15 mg dose, is an effective, rapidly acting, oral hypnotic agent with a low incidence of adverse effects.

The Acceptability of a Non-Benzodiazepine Hypnotic (Zopiclone) in General Practice

1983 ◽  
Vol 11 (6) ◽  
pp. 333-337 ◽  
Author(s):  
P J Chaudoir ◽  
N C Jarvie ◽  
G J Wilcox
Keyword(s):  
General Practice ◽  
Adverse Reactions ◽  
Sleep Onset ◽  
Residual Effects ◽  
Sleep Onset Latency ◽  
Onset Latency ◽  
Quality Of Sleep ◽  
Double Blind ◽  
Randomized Crossover Study

The hypnotic effects of Zopiclone, a novel cyclopyrrolone derivative, were compared with placebo in a double-blind randomized crossover study in insomniac patients. Subjective morning assessments by the patients showed that Zopiclone 7·5 mg improved the quality of sleep, with a reduction in the sleep onset latency and the number of nocturnal awakenings. Zopiclone was judged by the physicians to be superior to placebo and was preferred by the patients. Subjective residual effects and adverse reactions were minimal.

Opipramol Improves Subjective Quality of Sleep the Night Prior to Surgery: Confirmatory Testing of a Double-Blind, Randomized Clinical Trial

2011 ◽  
Vol 64 (1) ◽  
pp. 24-31 ◽  
Author(s):  
Michael Hueppe ◽  
David Hartge ◽  
Klaus-Dieter Stoll ◽  
Andrea Ros ◽  
Peter Schmucker ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Subjective Quality ◽  
Quality Of Sleep ◽  
Double Blind ◽  
Confirmatory Testing

ASSOCIATION BETWEEN QUALITY OF SLEEPAND OTHER PARAMETERS IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE.

2021 ◽  
pp. 25-27
Author(s):  
Umesh kr. Mishra ◽  
Sunita Tiwari ◽  
Sumit Rungta ◽  
Pooja Mishra ◽  
Gulam Akhtar
Keyword(s):  
Sleep Disorders ◽  
Quality Of Sleep ◽  
Night Time ◽  
Rem Latency ◽  
The Mean ◽  
Potential Impact ◽  
Nocturnal Polysomnography ◽  
The Impact ◽  
Gerd Symptoms

Background: Night time reux has been shown to be associated with fragmented sleep. However, few studies have assessed the quality of sleep on gastroesophageal reux and the impact of gastroesophageal reux on reported quality of sleep and quality of sleep on gastroesophageal reux. The aims of this study were to evaluate the quality of sleep and other parameters in patients with gastroesophageal reux disease.50 Subjects with typical GERD symptoms ≥3 times a week and All subjects were administered 3 questionnaires: PSQI , ESS, GERD-HRQL . All the subjects underwent nocturnal polysomnography and completed a all 3 questionnaire before NPSG. Results: Overall ,the mean percentage of N1 was 9.10±9.74 ,N2 was 83.97±13.81 , N3 was 3.44±4.16 , N4 was 0.60±2.04 , REM was 2.14±3.79 , PSQI was 12.48±1.23 , ESS was 11.80±0.76 , TST (hr) was 5.19±0.74 , SPT(hr) was 6.58±0.77 , sleep efciency(%) was 52.50±27.16 , Latency (mint) was 22.79±30.85 , REM Latency (mints) was 96.99±151.86 ,and Microarousal index was 36.05±25.93 . To assess the potential impact of sleep quality via nocturnal polysomnography on severity of gastroesophageal reux , we performed correlations between the GERD questionnaire and nocturnal polysomnography reports . We observed that PSQI(r= -0.285, p<0.045) , ESS(r=0.206, p=0.05) , N1(r=0.202 , p>0.160) , N2(r=- 0.045 ,p>0.758) , N3(r=-0.079, p>0.583) , N4(r-0.209 ,p>0.145),REM(r=0.045 ,p>0.756) , TST(r=0.036 ,p>0.803), SPT(r=0.015,p>0.917) , Sleep Efciency (r=-0.113,p>0.435) , Sleep Latency (r=-0.045 ,p>0.756), REM Latency (r=0.165, p >0.253), Microarousal index (r=0.058 , p>0.683). Conclusions: Gastroesophageal reux disease and sleep disorders are extremely prevalent conditions, and it seems intuitive that there must be some overlap between the two. Sleep disorders may in fact be one of the most prevalent of the extraesophageal complications of GERD and often goes unrecognized.

School Phobia: A Therapeutic Trial with Clomipramine and Short-Term Outcome

1981 ◽  
Vol 138 (2) ◽  
pp. 110-118 ◽  
Author(s):  
T. Berney ◽  
I. Kolvin ◽  
S. R. Bhate ◽  
R. F. Garside ◽  
J. Jeans ◽  
...  
Keyword(s):  
School Refusal ◽  
Therapeutic Trial ◽  
Short Term ◽  
Neurotic Disorder ◽  
Double Blind ◽  
Term Outcome ◽  
School Phobia ◽  
Short Term Outcome ◽  
Rapid Relief ◽  
Better Than

SummaryA double-blind trial failed to demonstrate any significant short-term effects of clomipramine in doses recommended for use in general practice (in addition to the usual range of psychotherapeutic help) in the treatment of children with school refusal and neurotic disorder. Patterns of improvement were also studied for the sample as a whole irrespective of treatment. Neither age nor sex were significantly related to improvement, except on one behavioural measure where girls initially did better than boys. In addition, it was found that there was a rapid relief of depression but neurotic symptomatology tended to persist.

The Impact of Emergency Surgery versus Self-expanding Metallic Stents on Anal Function and Quality of Life in Patients with Complete Obstructing Left-sided Colon Cancer

2021 ◽  
Author(s):  
GanBin Li ◽  
Tao Yu ◽  
Hao-Yu Zhang ◽  
Zhen-Jun Wang ◽  
Guang-Hui Wei ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colon Cancer ◽  
Regression Analysis ◽  
Short Term ◽  
Anal Function ◽  
Eortc Qlq C30 ◽  
Eortc Qlq ◽  
Better Than

Abstract Background: Emergence surgery (ES) and self-expanding metallic stents (SEMS) are traditional approaches for complete obstructing left-sided colon cancer. A strategy of “stents-chemotherapy-surgery” was applied in our center recently. Studies assessing the anal function and quality of life of patients with complete obstructing left-sided colon cancer are still lacking.Methods: Patients with complete obstructing left-sided colon cancer were included, and three treatment strategies were used, including ES, SEMS, and SEMS followed by neoadjuvant chemotherapy (NAC) for patients with complete obstructing left-sided colon cancer. The Wexner, Vaizey, and low anterior resection syndrome (LARS) scores were used to assess anal function and the EORTC QLQ C30 score was used to assess quality of life. Logistic regression analysis was used to detect risk factors affecting short-term anal function of patients.RESULTS: The Wexner scores were similar among the groups during the follow-up period. The Vaizey (H=18.415, P=0.001) and LARS scores (H=3.660, P=0.04) both revealed that anal function among patients receiving SEMS and NACwas significantly better than patients who underwent ES at the 1-month post-operative follow-up evaluation; no significant difference existed at the 6- and 12-month follow-up evaluations. The EORTC QLQ C30 score revealed that social function of patients receiving SEMS and NAC was also significantly better than patients undergoing ES (H=7.035, P=0.03). Logistic regression analysis suggested that a one-stage stoma in an emergent setting is an independent risk factor for short-term reduction of anal function among patients with complete obstructing left-sided colon cancer (OR=5.238, 95% CI: 1.569~17.484, P=0.007).Conclusion: Compared to ES, SEMS might be able to improve the quality of life and short-term anal function in patients with complete obstructing left-sided colon cancer.

scholarly journals Effect of short-term inhalation of warm saline atomised gas on patients with non-cystic fibrosis bronchiectasis

2020 ◽  
Vol 6 (1) ◽  
pp. 00130-2019 ◽  
Author(s):  
Lihong Zhong ◽  
Ying Xiong ◽  
Zeguang Zheng ◽  
Ni Liu ◽  
Jieying Hu ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Pulmonary Function ◽  
Inflammatory Factors ◽  
Aerosol Therapy ◽  
Short Term ◽  
Walk Distance ◽  
Leicester Cough Questionnaire ◽  
Better Than ◽  
Secretion Clearance

ObjectiveSecretion clearance is advocated in non-cystic fibrosis bronchiectasis, but is often neglected in clinical treatment. The present study aimed to investigate the effect of inhaled 0.9% normal saline by ultrasonic nebuliser with warming (UNW) in stable non-cystic fibrosis bronchiectasis patients with purulent sputum.Methods27 stable patients were enrolled in a randomised crossover trial comprising 3 months of daily UNW aerosol therapy compared with 3 months of daily oral expectorant treatment. The outcomes were quality of life (assessed via the Leicester cough questionnaire (LCQ)), sputum characteristics, pulmonary function, 6-min walk distance (6MWD) and acute exacerbation frequency.ResultsCompared with baseline, the sputum viscosity, sputum colour, LCQ score and 6MWD were significantly improved with UNW (p<0.05), and the improvements in sputum colour, LCQ score, 6MWD and inspirational capacity with UNW were significantly better than those achieved via treatment with oral expectorant (p<0.05). There were no significant differences between treatments in pulmonary function, sputum cytology classification and inflammatory factors of sputum.ConclusionUNW aerosol therapy in non-cystic fibrosis bronchiectasis has small yet significant benefits. However, UNW does not improve the degree of inflammation.

Sign in / Sign up

Export Citation Format

Share Document